Skip to Content

Holy Stone Healthcare Co Ltd 4194

Morningstar Rating
Unlock our analysis with Morningstar Investor

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

4194 is trading within a range we consider fairly valued.
Price
TWD 19.36
Fair Value
TWD 65.88
Uncertainty
Extreme
1-Star Price
TWD 178.68
5-Star Price
TWD 1.55
Economic Moat
Fcqj
Capital Allocation
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if 4194 is a good fit for your portfolio.

Trading Information

Previous Close Price
Day Range
52-Week Range
Bid/Ask
/
Market Cap
Volume/Avg
/

Key Statistics

Price/Earnings (Normalized)
Price/Sales
10.53
Dividend Yield (Trailing)
Dividend Yield (Forward)
Total Yield

Company Profile

Holy Stone Healthcare Co Ltd is a Taiwan based company focused on a biopolymer drug delivery platform. It is involved in the development of new drugs and medical devices, especially hyaluronic acid related therapeutic products. The products of the company include RenehaVis, SportVis, TRUD, and GAF.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Small Value
Total Number of Employees

Comparables

Valuation

Metric
4194
6838
1701
Price/Earnings (Normalized)
20.34
Price/Book Value
26.966.470.89
Price/Sales
10.5343.080.78
Price/Cash Flow
11.96
Price/Earnings
4194
6838
1701

Financial Strength

Metric
4194
6838
1701
Quick Ratio
0.894.400.87
Current Ratio
1.304.581.65
Interest Coverage
−408.91−52.207.38
Quick Ratio
4194
6838
1701

Profitability

Metric
4194
6838
1701
Return on Assets (Normalized)
−65.36%−14.76%2.57%
Return on Equity (Normalized)
−86.58%−21.79%4.40%
Return on Invested Capital (Normalized)
−76.74%−21.87%3.43%
Return on Assets
4194
6838
1701
See how this stock stacks up to its competitors with Morningstar Investor

Biotechnology Industry Comparables

Ticker
Name
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
NVO
Novo Nordisk A/S ADRCrygbtggBkfv$585.2 Bil
VRTX
Vertex Pharmaceuticals IncHxftkwkFmmlhrr$110.6 Bil
REGN
Regeneron Pharmaceuticals IncPktzdgkdQfsbxjk$107.6 Bil
MRNA
Moderna IncJdmpjjmnMycj$48.2 Bil
BNTX
BioNTech SE ADRYnkyzqntZfbpr$22.3 Bil
ARGX
argenx SE ADRNbdqplqbWxly$21.9 Bil
ALNY
Alnylam Pharmaceuticals IncZpkzqklvMdnhdm$19.0 Bil
BMRN
Biomarin Pharmaceutical IncDhnpxdzsNdqbzn$15.1 Bil
INCY
Incyte CorpPtlrstgMghwcv$12.8 Bil
RPRX
Royalty Pharma PLC Class AQfhxcfkgsdLsplzgv$12.7 Bil

Sponsor Center